Penserra Capital Management LLC Adverum Biotechnologies, Inc. Transaction History

Penserra Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$1.74 - $2.4 $3,915 - $5,400	-2,250 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.08 - $3.6 $41 - $72	20 Added 0.9%	2,250 $4,000
Q2 2021 Aug 12, 2021	BUY	$3.36 - $10.56 $84 - $264	25 Added 1.13%	2,230 $7,000
Q1 2021 May 13, 2021	SELL	$9.26 - $14.36 $277 - $430	-30 Reduced 1.34%	2,205 $21,000
Q4 2020 Feb 12, 2021	BUY	$9.84 - $14.26 $14,002 - $20,291	1,423 Added 175.25%	2,235 $24,000
Q3 2020 Nov 13, 2020	BUY	$10.3 - $21.64 $8,363 - $17,571	812 New	812 $8,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.